A profitable growth company, Genentech has a strong and diverse pipeline with more than 100 projects in development. Our total operating revenues for 2007 were approximately $11.7 billion, an increase of 26 percent from 2006, with total U.S. product sales of approximately $8.5 billion, a 19 percent increase from 2006.

We developed our Horizon 2010 vision and goals to help ensure that we are solidly positioned to fulfill our mission of discovering, developing, manufacturing and commercializing life-enhancing and life-extending medicines for patients with unmet medical needs. The Horizon 2010 goals started in 2006 and continue through the end of 2010. Read more >>

Development Pipeline In 2007, Genentech reinvested more than $2.4 billion, or 21 percent of operating revenues on a GAAP basis, into research and development. View our current pipeline.

Dow Jones Sustainability Index - North America Genentech was recognized as a corporate sustainability leader among healthcare companies and included as a component of the Dow Jones Sustainability Index effective September 22, 2008. Read more about our sustainability efforts and view or download our sustainability report.

Download Investor Fact Sheet (PDF/2.17MB)

Download 2007 Annual Report (PDF/2.16MB)

Quote: 73.00 Change: -5.75 Date: 10.10.08 Time: 16:02:00 Change: 20 min delay Use our interactive Genentech stock charts.